11 unknown, 8 completed, 4 recruiting, 2 active not recruiting. 6 Not applicable, 5 Phase 2, 2 Phase 1, 2 Phase 3, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 6 | Unknown 6 |
| Phase 2 | 5 | Completed 4, Withdrawn 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 3 | 2 | Completed 1, Recruiting 1 |
| Phase 4 | 2 | Recruiting 1, Unknown 1 |
Follow Prolactinoma: new trials by email Literature Review of Prolactinoma trials Research Report on Prolactinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Potency of a High Cabergoline Dosage in Microprolactinomas Cabergoline - Prolactinoma, Prolactin Excess | Phase 3 | Recruiting | University of Sao Paulo General Hospital | 70 | 2026-03-04 | 2026-03-13 |
| How Estrogen Fluctuations Before Diagnosis Affect the Size Prolactin-secreting Tumors Standardized questionnaire - Prolactinoma, Macroprolactinoma | Recruiting | Hospices Civils de Lyon | 180 | 2026-01-06 | 2026-01-22 | |
| Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment Cabergoline (Dopamine Agonist) - Prolactinoma | Phase 4 | Recruiting | University Hospital, Basel, Switzerland | 60 | 2025-09-16 | 2025-09-23 |
| The PROMISE Survey Prolactinoma, Pituitary Tumor | Active not recruiting | University Hospital, Basel, Switzerland | 530 | 2025-06-13 | 2026-01-08 | |
| Exercise Capacity and Physical Activity Level in Prolactinoma Patients Prolactinoma | Completed | Hacettepe University | 38 | 2021-06-16 | 2024-05-24 | |
| Validation of a Quality of Life Metric "Prolac-10" Prolactinoma, Prolactin-Producing Pituitary Tumor | Terminated | Ohio State University | 8 | 2019-10-15 | 2025-12-05 | |
| PRolaCT - Three Prolactinoma RCTs Endoscopic trans-sphenoidal adenoma resection, Dopamine Agonists - Prolactinoma, Prolactin-Producing Pituitary Tumor | Phase 4 | Unknown | Leiden University Medical Center | 880 | 2019-06-21 | 2020-07-20 |
| Dopamine D2 Receptors(D2R) Imaging in Prolactinomas Surgery, Drug treatment - Prolactinoma | Not applicable | Unknown | Zhebao Wu | 50 | 2018-12-01 | 2018-11-20 |
| Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas HCQ/CQ and CAB combined treatment - Resistance, Disease, Prolactinoma | Not applicable | Unknown | Zhebao Wu | 30 | 2018-10-25 | 2018-10-16 |
| Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma Cabergoline - Pituitary Adenoma, Prolactinoma | Not applicable | Unknown | Seoul National University Hospital | 68 | 2018-02-22 | 2020-03-18 |
| Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole Ropinirole - Hyperprolactinemia, Prolactinoma | Phase 1 / Phase 2 | Completed | Columbia University | 16 | 2016-09-16 | 2024-06-04 |
| Dopamine Agonists Withdrawal Study of Invasive Prolactinomas Involving the Cavernous Sinus Invasive Prolactinomas Involving the Cavernous Sinus | Unknown | Zhebao Wu | 30 | 2016-06-01 | 2017-05-16 | |
| Study on Therapy of Non-invasive Prolactinoma transsphenoidal surgery treatment, dopamine agonist treatment - Prolactinoma | Not applicable | Unknown | First Affiliated Hospital, Sun Yat-Sen University | 394 | 2016-01-01 | 2017-11-24 |
| Seoul National University Pituitary Disease Cohort Study Dynamic hormone study and Magnetic resonance imaging - Pituitary Disease, Pituitary Incidentaloma | Unknown | Seoul National University Hospital | 1600 | 2015-03-15 | 2020-03-18 | |
| Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools Educational Intervention - Pituitary Neoplasms, Prolactinoma | Not applicable | Unknown | Unity Health Toronto | 60 | 2014-02-01 | 2015-07-31 |
| Rhinological Outcomes in Endonasal Pituitary Surgery Pituitary Neoplasm, Pituitary Adenoma | Completed | St. Joseph's Hospital and Medical Center, Phoenix | 235 | 2011-10-01 | 2018-08-22 | |
| Efficacy of Rapid Escalation of Cabergoline in Comparison to Conventional Dosing in Prolactin Secreting Macroadenomas. Cabergoline, cabergoline - Macroprolactinoma | Not applicable | Unknown | Post Graduate Institute of Medical Education and Research, Chandigarh | 20 | 2010-05-01 | 2010-06-14 |
| Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia gamma-secretase/Notch signalling pathway inhibitor RO4929097, diagnostic laboratory biomarker analysis, pharmacological study - Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 129 | 2010-03-01 | 2014-11-05 |
| Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas Pasireotide, cabergoline - Non-functioning Pituitary Adenomas, Prolactinomas | Phase 2 / Phase 3 | Completed | Universidade Federal do Rio de Janeiro | 21 | 2010-03-01 | 2016-08-22 |
| Temozolomide in Treating Patients With Invasive Pituitary Tumors temozolomide, DNA methylation analysis, microarray analysis - Brain and Central Nervous System Tumors | Phase 2 | Withdrawn | Jonsson Comprehensive Cancer Center | 2009-12-01 | 2020-07-31 |
Showing 20 of 28. Sign in to see all of them.
Pituitary Neoplasms (13) · Acromegaly (6) · Hyperprolactinemia (4) · Pituitary Diseases (3) · Adenoma, Acidophil (2) · Adenoma, Basophil (2) · Adenoma, Chromophobe (2) · Gigantism (2) · Growth Hormone-Secreting Pituitary Adenoma (2) · Pituitary ACTH Hypersecretion (2) · Recurrence (2) · ACTH-Secreting Pituitary Adenoma (1) · Adenoma (1) · Adrenocortical Hyperfunction (1)
Brain Diseases (28) · Central Nervous System Diseases (28) · Endocrine Gland Neoplasms (28) · Endocrine System Diseases (28) · Hypothalamic Diseases (28) · Neoplasms by Histologic Type (28) · Neoplasms by Site (28) · Neoplasms, Glandular and Epithelial (28) · Nervous System Diseases (28) · Adenoma (27) · Neoplasms (27) · Pituitary Diseases (25) · Pituitary Neoplasms (15) · Brain Neoplasms (13) · Hypothalamic Neoplasms (13)
Cabergoline (6) · Dopamine Agonists (2) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1) · Calcium Dobesilate (1) · Clomiphene (1) · DNA Methylation (1) · Dexamethasone (1) · Early Intervention, Educational (1) · Lapatinib (1) · Magnetic Resonance Spectroscopy (1) · Microarray Analysis (1) · Standard of Care (1) · Surgical Procedures, Operative (1) · Temozolomide (1) · Tissue Banks (1)
Zhebao Wu (3) · Cedars-Sinai Medical Center (2) · Hospices Civils de Lyon (2) · Seoul National University Hospital (2) · Universidade Federal do Rio de Janeiro (2) · University Hospital, Basel, Switzerland (2) · Columbia University (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · Federal University of São Paulo (1) · Federico II University (1) · First Affiliated Hospital, Sun Yat-Sen University (1) · Hacettepe University (1) · Jonsson Comprehensive Cancer Center (1) · Leiden University Medical Center (1) · National Cancer Institute (NCI) (1)
United States (7) · Brazil (4) · China (3) · Canada (2) · France (2) · South Korea (2) · Switzerland (2) · India (1) · Italy (1) · Netherlands (1) · Turkey (Türkiye) (1)
Jung Hee Kim, M.D (2) · Andrew S. Little, MD (1) · Anil Bhansali, MD DM (1) · Annamaria AL Colao, Prof. (1) · Anthony Heaney, MD (1) · Ashu Rastogi, MD (1) · Cihan Atila (1) · Cihan Atila, Dr. (1) · Deborah P Merke, M.D. (1) · Douglas Hardesty, MD (1) · Ebru Calik Kutukcu, PhD (1) · Erika CO Naliato, MSc (1) · Gabrielle Page-Wilson, M.D. (1) · Gerald Raverot, MD PhD (1) · Haijun Wang, Dr. (1)
PMID 11880025, PMID 12390688, PMID 12934784, PMID 14627787, PMID 15081648, PMID 16148287, PMID 16267335, PMID 16705142, PMID 17202453, PMID 17202454, PMID 18682513, PMID 19170709, PMID 19344074, PMID 21296991, PMID 22154461, PMID 23347435, PMID 23662829, PMID 23824978, PMID 24412141, PMID 25024426, PMID 25258026, PMID 25839931, PMID 25884256, PMID 26473774, PMID 27496264, PMID 27864853, PMID 28651368, PMID 28973192, PMID 29395172, PMID 30234410, PMID 32232325, PMID 32714280, PMID 33150390, PMID 34563236, PMID 35954244, PMID 36149413, PMID 37715962, PMID 38801597, PMID 40813536, PMID 41349930, PMID 41540017
2025 (2), R21DK112093 (1), U01CA097452 (1)